{
  "id": 1648350,
  "title": "Cue Biopharma legal chief sells $265,627 in common stock",
  "url": "https://urgent.news/2026/08/18/cue-biopharma-legal-chief-sells-265-627-in-common-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-18T06:05:56.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/cue-biopharma-legal-chief-sells-265627-in-common-stock-93CH-4864295"
  },
  "original_language": "en",
  "account": "Sumita Ray, Chief Legal Compliance Officer and Corporate Secretary at Cue Biopharma, sold 8,829 shares of the company's common stock on August 13, 2026, for a total of $265,627. This was after she had purchased 18,196 shares through the exercise of derivative securities. The sales were at prices between $29.37 and $31.13 per share. These transactions were to cover tax withholding obligations for the vesting and settlement of performance stock units. This is not a discretionary move by Ray. Cue Biopharma's stock surged by 210% over the last six months, which is why these performance-based PSUs are vesting. The company is still considered undervalued according to Fair Value analysis.",
  "summary": null,
  "key_points": [
    "Sumita Ray sold 8,829 Cue Biopharma shares for $265,627 on August 13, 2026.",
    "Sales price ranged from $29.37 to $31.13 per share.",
    "Transactions covered tax withholding for performance stock units."
  ],
  "editors_take": "The sale of Cue Biopharma shares by its legal chief to cover tax obligations suggests that the company's recent 210% stock surge is translating into windfalls for executives tied to performance-based stock units.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}